The U.S. Food and Drug Administration approved Regeneron’s garetosmab for a disease that causes dangerous bone growth.

The disease description is broadly accurate. Fibrodysplasia ossificans progressiva, or FOP, is a rare genetic disorder in which soft tissues such as muscles, tendons, and ligaments can gradually turn into bone, creating abnormal bone growth and a progressively formed second skeleton.

However, the claim specifically says that the FDA approved garetosmab. The provided evidence does not establish that final regulatory action occurred:

• Regeneron’s announcement states that the FDA accepted the biologics license application for priority review, which is a review status, not an approval decision.
• The Globe and Mail and Nasdaq items, both dated February 19, 2026, likewise describe acceptance for priority review and refer to a future FDA decision date.
• Reuters, STAT, and Regeneron’s Phase 3 announcement describe positive clinical-trial results, but successful trial results do not by themselves constitute FDA approval.
• The search results include no FDA approval announcement, FDA prescribing information, approval letter, or later reliable report confirming a final approval by August 19, 2026.

The first three sources are unrelated Bureau of Labor Statistics pages about occupations and pharmacy employment, so they provide no evidence about garetosmab or FDA action. The available evidence therefore supports the narrower statement that garetosmab was being evaluated by the FDA for FOP, not the definitive statement that it had been approved.